Kine Sciences Co., Ltd.

This was a small, early-stage study to check if a new drug called KINE-101 is safe for people with a chronic nerve disease called CIDP, when standard steroid treatments haven't worked. Nine patients received a single intravenous dose at one of three increasing levels and were mon…

This was an early safety study to see how healthy adults tolerate a new drug called KINE-101. Twenty-four healthy volunteers received daily intravenous doses for one week at three different dose levels, while some received a placebo. The main goal was to check for side effects an…

This is the first study to test a new drug called KINE-101 in humans. It enrolled 40 healthy volunteers to check if the drug is safe and to see how the body absorbs and processes it. Participants received either the drug or a placebo (inactive substance) as a single injection or …